Communiqués Medigene AG OTC Markets

Actions

MDGEF

DE000A1X3W00

Marché Fermé - OTC Markets Autres places de cotation 15:36:56 28/03/2024			Varia. 5j.	Varia. 1 janv.
2,297 ^USD	-11,96%		-5,49%	+53,10%

03/07	Medigene AG élargit son portefeuille de brevets avec la délivrance d'un brevet pour son récepteur de cellules T ciblant NY-ESO-1/LAGE 1a en Chine	CI
27/06	Medigene présente un processus efficace de production de thérapie TCR-T en 6 jours avec un taux de germination élevé	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	03/07	GL
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	27/06	GL
Medigene Reports Results of Annual General Meeting	24/06	GL
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024	21/06	GL
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors	20/06	GL
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors	20/06	AQ
Medigene : Expands its End to End Platform by Submitting Three Patents to the European Patent Office	19/06	PU
Medigene : Release according to Article 40, Section 1 of the WpHG	19/06	PU
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office	28/05	GL
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term	21/05	GL
Medigene : Description of the remuneration system for Supervisory Board members	17/05	PU
Medigene : Report of the Executive Board on agenda item 8	17/05	PU
Medigene : Report of the Executive Board on agenda item 9	17/05	PU
Medigene : Explanations of the rights of shareholders	17/05	PU
Medigene : Proxy to third person	17/05	PU
Medigene : Data protection information	17/05	PU
Medigene : CV Dr. Gerd Zettlmeissl	17/05	PU
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05	GL
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05	AQ
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise	14/05	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Medigene AG OTC Markets

Actions

MDGEF

DE000A1X3W00

Communiqués

Filtres